Impact of AI-quantified fluid dynamics on visual outcomes over 5 years in patients with treatment-naïve nAMD from the FRB! registry.

Philipp Fuchs¹, Ursula Schmidt-Erfurth^2,3, Leonard M Coulibaly¹, Hrvoje Bogunovic¹, Oliver Leingang¹, Anastasiia Gruber^1,4, Florian Frommlet⁴, Virginia Mares^1,5, Daniel Barthelmes⁶, Gregor S Reiter¹

¹Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.

²Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria. Ursula.schmidt-erfurth@meduniwien.ac.at.

³, Währinger Gürtel 18-20, Vienna, 1090, Austria. Ursula.schmidt-erfurth@meduniwien.ac.at.

⁴Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.

⁵Department of Ophthalmology, Federal University of Minas Gerais, Belo Horizonte, Brazil.

⁶Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland.

PubMed PMC DOI PDF

Abstract

To investigate the impact of retinal fluid dynamics on visual outcomes in patients with treatment-naïve neovascular age-related macular degeneration (nAMD) treated in the real world over 5 years using approved AI-based fluid monitoring. Real-world data comprising OCT scans and electronic medical records from 148 patients (187 eyes) were extracted from the Fight Retinal Blindness! (FRB! ) Zürich da…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.